Ovarian hyperstimulation syndrome
Conditions
Interventions
treatment group(study group ):combination of GnRH - A and letrozole with mifepristone will be used for High-risk early-onset OHSS patients after oocyte retrieval
The control group (mifepristone):mifepristone will be used for High-risk early-onset OHSS patients after oocyte retrieval
Sponsors
International Affairs Office, Wuhan University Renmin Hospital (Hubei General Hospital)
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Women in the first IVF/ICSI cycle of 20-40 years; 2. the number of ovum recovery over than 18; 3. Serum E2 is greater than 5000pg/ml on the day of HCG trigger ; 4. Cancel the fresh embryo transplantation and frozen the whole embryos; 5. HCG trigger.
Exclusion criteria
Exclusion criteria: 1. Allergy to GnRH-A(cetrorelix) or mifepristone and letrozole; 2. Measures taken to prevent OHSS (such as coasting, etc.) are used duing the ovarian stimulation process. 3. Some systemic diseases (liver and kidney disease, diabetes, hypercholesterolemia, Cushing's syndrome, adrenal cortical dysfunction, venous thrombosis, pulmonary embolism, or cerebrovascular events); 4. Any drug (cox-2 inhibitor, calcium antagonist, etc.) that can influence the permeability of blood vessels (cox-2 inhibitor, calcium antagonist, etc.) before the cycle, and th drugs (insulin sensitizer) that affects endocrine; 5. GnRHa or GnRHa+HCG double trigger.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of moderate plus severe OHSS in both groups; | — |
Secondary
| Measure | Time frame |
|---|---|
| The period of the luteus of in both groups;VEGF levels in serum in both groups; | — |
Countries
China
Contacts
Public ContactQing-Zhen Xie
International Affairs Office, Wuhan University Renmin Hospital(Hubei General Hospital)
Outcome results
None listed